Magtrace for Delayed SLNB in DCIS
High-Risk Ductal Carcinoma In Situ (DCIS) / Early Breast Cancer Staging
Post-Market StudyActive
Key Facts
Indication
High-Risk Ductal Carcinoma In Situ (DCIS) / Early Breast Cancer Staging
Phase
Post-Market Study
Status
Active
Company
About Endomag
Endomag is a commercial-stage diagnostics company that has developed Magtrace®, a magnetic nanoparticle tracer for sentinel lymph node biopsy in breast cancer. Its technology enables a 'Delayed SLNB' approach, potentially allowing up to 80% of high-risk DCIS patients to avoid unnecessary axillary surgery. The company's platform, which includes the Sentimag® detection probe, provides a clinically effective, radiation-free, and more convenient solution for cancer staging, with over 200,000 patients treated globally.
View full company profile